search
Back to results

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

Primary Purpose

Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy

Status
Unknown status
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Chlorhexidine
Povidine-Iodine
Sponsored by
MidAtlantic Retina
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Age-related Macular Degeneration

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Current patient of the Wills Eye Hospital Retina Service including all Mid Atlantic Retina offices
  • Clinical indication of bilateral intravitreal injection as determined by the treating retina specialist for a diagnosis of age-related macular degeneration, diabetic macular edema, proliferative retinopathy or macular edema associated with retina vein occlusion.
  • Age greater than 18.

Exclusion Criteria:

  • Documented allergy to PI or AC
  • Current diagnosis of infectious keratitis
  • History of unilateral contact lens wear in the past 30 days
  • Current unilateral use of prescription eye drops.

Sites / Locations

  • MidAtlantic RetinaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Povidine-Iodine

Chlorhexidine

Arm Description

Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye

Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye

Outcomes

Primary Outcome Measures

Patient Comfort
Patient Comfort using the Wong Baker FACES Pain Scale [Scale: 0(No pain) - 10 (Worst Pain)]

Secondary Outcome Measures

Culture of conjunctiva for bacteria
Microbial flora
Patient Comfort
Patient Comfort using the Wong Baker FACES Pain Scale [Scale: 0(No pain) - 10 (Worst Pain)]

Full Information

First Posted
May 10, 2018
Last Updated
June 25, 2018
Sponsor
MidAtlantic Retina
search

1. Study Identification

Unique Protocol Identification Number
NCT03571100
Brief Title
Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections
Official Title
Patient Comfort and Antimicrobial Efficacy With Aqueous Chlorhexidine Versus Povidine-Iodine (Betadine) as Ocular Surface Disinfectant Prior to Intravitreal Injection
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Unknown status
Study Start Date
May 7, 2018 (Actual)
Primary Completion Date
May 6, 2019 (Anticipated)
Study Completion Date
May 6, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
MidAtlantic Retina

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this prospective interventional study is to compare patient experience, ocular surface irritation, and bacterial colony counts and microbial spectrum between povidine iodine and aqueous chlorhexidine as ocular surface antiseptic prior to intravitreal injection
Detailed Description
This is a single center prospective study comparing antiseptic efficacy and ocular surface irritation with PI (povidine iodine) and AC (aqueous chlorhexidine). Patients will be recruited in the clinical offices of the Retina Service of Wills and Hospital/Mid Atlantic Retina clinic offices. Patients who are determined to require bilateral intravitreal injections of an anti-VEGF (vascular endothelial growth factor) agents by a retina specialist at their regularly scheduled retina appointment will be evaluated for qualification by study personnel. Patients who meet inclusion criteria will be identified and informed consent will be obtained. Prior to injection, topical anesthetic (0.5% proparacaine, Alcon) will be instilled in both eyes. Study personnel will obtain four samples from the superior and inferior fornices of the upper and lower lids of both eyes using swabs (COPAN ESwab, ThermoFisher Scientific) for patients enrolled at Wills. Topical antisepsis will then be applied, the first eye will be randomized to one drop of either PI 5% or AC 0.1% and the second eye will receive the other agent. One minute after instillation of the eye drop to each eye, patients will rate their pain in each eye using the Wong-Baker (smiley face) rating scale. The injections will then be performed by the treating retina specialist. Following the injection, a second conjunctival culture will be taken in an identical manner to the first for patients enrolled at Wills. Study personnel will then instill fluorescein dye (fluorescein sodium ophthalmic, BioGlo) into each eye, and a brief slit lamp examination will be performed. Study personnel will record surface findings according to the Ocular Surface Score and a numerical score for each eye will be determined. On post-injection day one study personnel will call the patient and ask to rate the pain in each eye using the same verbal numerical rating scale. No additional clinic visits will be required as part of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy, Retina Vein Occlusion

7. Study Design

Primary Purpose
Prevention
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Randomized prospective trial
Masking
Participant
Masking Description
The participant will be masked to which drug they receive, the investigator performing the analysis will also be masked
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Povidine-Iodine
Arm Type
Active Comparator
Arm Description
Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye
Arm Title
Chlorhexidine
Arm Type
Active Comparator
Arm Description
Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye
Intervention Type
Drug
Intervention Name(s)
Chlorhexidine
Other Intervention Name(s)
Aqueous chlorhexidine
Intervention Description
Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
Intervention Type
Drug
Intervention Name(s)
Povidine-Iodine
Other Intervention Name(s)
Betadine
Intervention Description
Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
Primary Outcome Measure Information:
Title
Patient Comfort
Description
Patient Comfort using the Wong Baker FACES Pain Scale [Scale: 0(No pain) - 10 (Worst Pain)]
Time Frame
One day following injection
Secondary Outcome Measure Information:
Title
Culture of conjunctiva for bacteria
Description
Microbial flora
Time Frame
7 days
Title
Patient Comfort
Description
Patient Comfort using the Wong Baker FACES Pain Scale [Scale: 0(No pain) - 10 (Worst Pain)]
Time Frame
I minute after drop instilled

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Current patient of the Wills Eye Hospital Retina Service including all Mid Atlantic Retina offices Clinical indication of bilateral intravitreal injection as determined by the treating retina specialist for a diagnosis of age-related macular degeneration, diabetic macular edema, proliferative retinopathy or macular edema associated with retina vein occlusion. Age greater than 18. Exclusion Criteria: Documented allergy to PI or AC Current diagnosis of infectious keratitis History of unilateral contact lens wear in the past 30 days Current unilateral use of prescription eye drops.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michele Formoso
Phone
215-928-3092
Email
research@midatlanticretina.com
First Name & Middle Initial & Last Name or Official Title & Degree
Devida Long
Phone
215-928-3092
Email
research@midatlanticretina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sunir Garg, MD
Organizational Affiliation
MidAtlantic Retina
Official's Role
Principal Investigator
Facility Information:
Facility Name
MidAtlantic Retina
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Formoso
Phone
215-928-3092
Email
research@midatlanticretina.com
First Name & Middle Initial & Last Name & Degree
Devida Long
Phone
215-928-3092
Email
research@midatlanticretina.com
First Name & Middle Initial & Last Name & Degree
Sunir Garg, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33221515
Citation
Ali FS, Jenkins TL, Boparai RS, Obeid A, Ryan ME, Wibblesman TD, Chiang A, Garg SJ; Post-Injection Endophthalmitis Study Group. Aqueous Chlorhexidine Compared with Povidone-Iodine as Ocular Antisepsis before Intravitreal Injection: A Randomized Clinical Trial. Ophthalmol Retina. 2021 Aug;5(8):788-796. doi: 10.1016/j.oret.2020.11.008. Epub 2020 Nov 20.
Results Reference
derived

Learn more about this trial

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

We'll reach out to this number within 24 hrs